Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI moved a median of 0.00% 30 minutes after news, and -0.85% by the close. How BCLI actually reacts to news — the realized, point-in-time move the market made, measured across 660 labeled events over the last three years with zero look-ahead.
BCLI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 653 |
| 30-min | 0.00% | 47% | 658 |
| 60-min | -0.77% | 38% | 659 |
| to close | -0.85% | 43% | 659 |
| Middle 50% of BCLI reactions | -4.48% to +1.10% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 660 |
Half of all Brainstorm Cell Therapeutics Inc. news events land between -4.48% and +1.10% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BCLI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCLI's baseline. Nothing else.
Recent BCLI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions | Press release | PR Newswire | -8.15% | +2.04% | |
| BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | +9.64% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +9.64% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +9.64% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman | Press release | PR Newswire | +2.09% | +0.00% | |
| Form EFFECT BRAINSTORM CELL THERAPEU | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.16% | |
| BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine | Press release | PR Newswire | +0.00% | +11.34% | |
| BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors | Press release | PR Newswire | +0.00% | +6.03% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form S-1 BRAINSTORM CELL THERAPEU | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -2.32% | |
| Form S-8 BRAINSTORM CELL THERAPEU | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.32% | |
| BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market | Press release | PR Newswire | +0.00% | +2.06% | |
| BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | -1.41% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.41% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.41% | |
| BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.67% | +6.24% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.67% | +6.24% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +6.24% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.53% | |
| Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February | Press release | PR Newswire | +0.00% | +15.83% | |
| Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market | Press release | PR Newswire | +13.68% | +28.42% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Feb 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.15% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -10.76% | |
| BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | +10.82% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +10.82% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +10.82% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Oct 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.69% | |
| Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | +0.00% | +2.86% | |
| BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -5.80% | -12.54% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.80% | -12.54% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -5.80% | -12.54% | |
| BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update | Press release | PR Newswire | +14.38% | +2.04% | |
| Form RW BRAINSTORM CELL THERAPEU | SEC filing · Form RW | SEC EDGAR | +0.28% | +0.72% | |
| BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB | Press release | PR Newswire | +0.00% | +20.00% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +20.00% | |
| FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness | Press release | PR Newswire | -1.67% | +9.17% | |
| Form S-8 BRAINSTORM CELL THERAPEU | SEC filing · Form S-8 | SEC EDGAR | +0.86% | -1.72% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | -6.03% | |
| Form S-3 BRAINSTORM CELL THERAPEU | SEC filing · Form S-3 | SEC EDGAR | +0.14% | -6.03% | |
| BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® | Press release | PR Newswire | -1.32% | +8.77% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | -4.80% | |
| BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials | Press release | PR Newswire | -4.62% | +0.00% | |
| BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS | Press release | PR Newswire | +11.01% | -19.05% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -5.39% | -3.13% | |
| Form ARS BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.86% | +13.79% | |
| Form DEF 14A BRAINSTORM CELL THERAPEU For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +0.86% | +13.79% | |
| Form DEFA14A BRAINSTORM CELL THERAPEU | SEC filing · Form DEFA14A | SEC EDGAR | +0.86% | +13.79% | |
| BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.86% | +13.79% | |
| BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 | Press release | PR Newswire | -9.52% | -7.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCLI section they belong to.
Where else BCLI is measured.
BCLI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Brainstorm Cell Therapeutics Inc.'s median reaction calculated?
Every labeled BCLI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 660 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of BCLI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCLI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.